超低剂量里瓦洛克萨班在患有心房的非常老年患者中的真实世界比较研究
Dan Han1, Qian Ni2, Jialin Qi2
1Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, People's Republic of China.
Clinical interventions in aging
|December 15, 2025
概括
超低剂量里瓦罗克萨班 (每天5毫克) 在患有非膜性心房动 (AF) 的非常老年患者中显示出与较高剂量相比的疗效. 这种疗法显著减少了重大出血事件,为这种高风险人群提供了一个平衡的选择.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 老年病的医生 老年病的医生
背景情况:
- 在非常老年 (≥80岁) 患有非膜性心房动 (AF) 的患者中,利瓦罗克萨班的最佳剂量仍在争论中.
- 临床医生判断的超低剂量 (每日5毫克) 疗法需要对现实世界的结果进行评估.
研究的目的:
- 为了比较临床医生选择的里瓦罗克萨班剂量在非常老的非膜性AF患者的现实结果.
- 评估每日5 mg,10 mg和15/20 mg利瓦洛克萨班剂量的疗效和安全性.
主要方法:
- 对1389名非常年长的非膜性AF患者 (2018-2022) 的回顾性研究.
- 患者每天接受里瓦罗克萨班5毫克,10毫克或15/20毫克.
- 治疗权重的稳定反向概率 (IPTW) 平衡的基线特征.
主要成果:
- 在IPTW后的三组里瓦洛克萨班剂量组中,复合疗效结果 (中风,血栓塞,心肌梗塞,心血管死亡) 没有显著差异.
- 主要出血率随剂量增加:1.6% (5毫克),3.6% (10毫克) 和6.1% (15/20毫克).
- 15/20毫克组与5毫克组相比,大出血风险显著增加 (HR:4.27).
结论:
- 超低剂量里瓦罗克萨班 (每天5毫克) 在非常老年AF患者中显示出与更高剂量相比的有效性.
- 与较高剂量相比,每日5毫克的治疗方案显著减少了主要出血.
- 临床医生选择的超低剂量里瓦罗克萨班可能为高风险老年人群提供平衡的疗效安全性.
相关概念视频
Drug Dosing: Geriatric Patients
209
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
209
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Pharmacodynamics in Geriatric Patients: Effects of Age
175
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
175
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
217
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
217
Bioavailability Study Design: Healthy Subjects Versus Patients
133
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
133
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
215
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
215


